ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common...

Full description

Bibliographic Details
Main Authors:	Rahmani, NE, Ramachandra, N, Sahu, S, Gitego, N, Lopez, A, Pradhan, K, Bhagat, TD, Gordon-Mitchell, S, Pena, BR, Kazemi, M, Rao, K, Giricz, O, Maqbool, SB, Olea, R, Zhao, Y, Zhang, J, Dolatshad, H, Tittrea, V, Tatwavedi, D, Singh, S, Lee, J, Sun, T, Steidl, U, Shastri, A, Inoue, D, Abdel-Wahab, O, Pellagatti, A, Gavathiotis, E, Boultwood, J, Verma, A
Format:	Journal article
Language:	English
Published:	Springer Nature 2021

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

Similar Items